A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the ...
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half ...
Understanding how a healthy brain works can provide insight into how it fails, too. Scientists hope that studying organoids derived from humans with neurodevelopmental disorders — particularly ...
As a part of this development strategy, Curanex will continue to advance its botanical drug development program in a stepwise ...
The Trump administration has pledged to conduct its own studies, but research continues to contradict its claims.
Human data and samples are scientific gifts, and scientists must be stewards of them, ensuring that they are collected and ...
Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state of the art 78,000 square foot facility located in Costa Mesa, ...
Q4 2025 Management View Randy Teel, CEO, stated the company is entering a period with "multiple value-driving milestones," highlighting Arvinas' first new drug application submission, which may lead ...
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, including for rare genetic conditions that the ...
The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results